Table 2.

What disease sites/treatments are currently being delayed? (N = 115 participants)

Participants	N	%
Early stage breast∗	49	42.6
Locally advanced breast	4	3.5
Small cell lung	3	2.6
NSCLC early stage SBRT	3	2.6
NSCLC locally advanced	2	1.7
Early stage definitive HN	4	3.5
Locally advanced definitive HN	2	1.7
Post-operative adjuvant HN	8	7.0
CNS—low grade glioma∗	28	24.3
CNS—high-grade glioma	2	1.7
CNS—GBM	3	2.6
GI—Esophageal/gastric	3	2.6
GI—pancreas	1	0.9
GI—liver	5	4.3
GI—rectal	2	1.7
GI—anal	2	1.7
Prostate—low risk∗	77	67.0
Prostate—intermediate risk∗	48	41.7
Prostate—high-risk∗	16	13.9
Bladder	2	1.7
Sarcoma	2	1.7
GYN—cervical	4	3.5
GYN—uterine	9	7.8
GYN—vagina/vulva	2	1.7
Palliative non-emergent∗	27	23.5
Palliative emergent	1	0.9
Oligometastatic SBRT	8	7.0
Cutaneous: melanoma	6	5.2
Cutaneous: Non-melanoma∗	19	16.5
Nonmalignant conditions∗	49	42.6
Lymphomas and leukemia	5	4.3
Pediatric high-grade CNS	3	2.6
Pediatric low-grade CNS	13	11.3
Pediatric solid tumor	3	2.6
Pediatric leukemia/lymphoma	5	4.3
None of the above	20	17.4

Abbreviations: CNS = central nervous system; GBM = glioblastoma; GI = gastrointestinal; GYN = gynecologic; HN = head and neck; NSCLC = non-small cell lung cancer; SBRT = stereotactic body radiation therapy.

^∗Most frequent results.